Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Not sure if this posted already but highlights scale of H&W ambitions - 1200 jobs is not small time and shows the current massive disconnect in value:
hTtps://www.business-live.co.uk/manufacturing/harland-wolff-provides-update-77m-28041809
Agreed the discount to NAV (which to my knowledge remains the same) is now totally overdone. There has been a significant number of AT trades so would not be surprised to see someone mopping up the sells over the last few weeks as SP walked down - hope to see a sustained recovery soon!
HtTps://www.ukib.org.uk/sites/default/files/2023-09/UKIB-Strategy-Update-Private-Sector-Investments.pdf
Page 10 highlights significant short term storage demands (including BESS) ; bodes well for GSF
I've emailed my local MP , the UK government has significant R&D budget for science (£39 B over 3 years) - may be 4D can tap into that as a lifeline?
I have invested in one or two listed companies previously where administration signalled the end - but like others here do not believe 4D is dead just yet!!
I agree Roache1. I invested in 4D on basis of science point to the next big leap in therapeutics. Definitely after the OF deal there has been continued unscrupulous dealings to work the price down for someone’s benefit. Don’t know if DP was complicit or powerless (certainly seems clueless) but any good RNS’ was followed by massive selling to undermine any potential SP rise - which to me suggests some background manipulation.
I know it’s slim chance now but hopeful there may be some return from administrators letting this continue as a going concern. I lost too much to leave without trying all options.
Finally, I was wondering if shareholders all write to their local MPs? I think there was post earlier 4D has close to 100 employees - all likely to lose jobs if a solution not found very soon. Plus this was a leading edge biotech firm and surely there must be R&D funding or some credit via the government to support such businesses where there is evidence of novel scientific life saving solutions. I mean people were claiming bounce back / covid19 interruption loans for more than the £ 12m needed by 4D to get OF off its back!!
Given the great news today I wouldn't be surprised if UK government and most likely US gov has bought up allocations (in advance of final approval) i.e. first dibs - that's the one thing the UK government has got right (buying circa 300m doses of vaccines 'at risk' before any final approval). So with current manufacturing capacity SNG could soon be conceivably cranking out stockpiles ready to hit the ground when MHRA/FDA approval granted.
Obviously this will not be in the public domain and cannot be RNS'd !! But it happened with vaccines and given the current situation with hospitals capacity shortfall I can see a similar approach being adopted for SNG's product.
Not showing here but available on ADVFN
Sandgrove has reduced its holding from around 10% to just under 5%.
Probably explains lack of share price movement past few days despite the Hercules good news
4.5m buys vs. 1.1m sell - yet down over 7%
Obviously IIs looking for shares off the back of today's news - we should expect a major reversal soon
This confirms Hercules is willing to take a short term hit for the bigger long term prize, and better still they (Hercules) have confidence that MTFB can agree a suitable plan for approval with the FDA (and finally reading between the lines not a massive re-trial but a tactical approach to allay FDA concerns).
Today's RNS would seem to suggest MTFB is carrying on with business as usual, whilst i admit a funding update would be reassuring, the fact lenders aren't holding BOD at ransom and big II's have held firm is also reassuring in its own way i.e. they must have some confidence that MTFB can actually navigate its way to an approval.
It's worth remembering when Iclaprim is approved Motif will have 20 year patent. I have experience of existing antibiotic sales and demand and can see demand for this growing, starting with US then register Europe and then roll-out to other big markets (China, Middle-East, Brazil, India etc.) with further scope other multiple use cases and combination products (similar to amoxi-clav) even a lower end this is likely to get to over £500m pa revenue in 3-4 four years post approavl but ,imo, upside longer term is much greater.
Estimate the ROI over 20 years - multi-billion reveneue is quite conceivable. Plus this is not like oil exploration where one duster you throw in the towel as there is existing supply; here is a life saving product in an environment where anti-microbial resistance is a massive risk over the next few years and there is a pressing need for new antibiotics. Hence I sense the confidence from MTFB that by hook or by crook this will make it over the line.
MMs still manipulating SP ; buys 2x sells yet still ~6%.; dropped Bid to flush panicked sellers but not really working!!
Behind the scences someone seems to be hoovering up shares which can only be good.
Maybe, just maybe, given the urgency for getting new antibiotics onto the market the FDA could fast-track the meeting? MTFB has to report the standard timelines so saying 60 days - but I get the feeling there are some positive vibes behind the scenes atm and not in as dire a position as some would have us believe.
All AT sells today (trying to dislodge more holders) - at some point this will blow...
Could be an interesting afternoon!
A big chunk of sells this morning were AT trades so MMs up to the usual tricks (presumably to get shares on on cheap for a big buyer in the wings).
Just hold for now (imo) and they will have to raise bid!!
Wisha - there is definitely something brewing ; Nasdaq up 11% and MMs trying to get shares but struggling even though bid raised sharply - with AMP out the way the downward volatility of past few weeks is not there anymore.
if MM want shares in any sizeable quantity there's only one option - increase price significantly! (5p+)
Taking an optimistic view the on basis: 1) GL said in June brief full phase 3 not required but additional data was needed to address FDA concerns on liver toxicity and MTFB developing a proposal - which it has done today. 2) Also funders (i.e Hercules) still on board. 3) We know talks with potential partners happening in background - indicating various funding options in place.
(imo) This suggests there are good prospects for a way forward and getting this over the approval line and still return shareholder value if the proposal is deemed acceptable. I know we have had massive setbacks (I bought at 40p and averaged down so sittiing on a large paper loss) but still holding and reckon overall a very good chance this will come good.
Looks like last of AMP holding being sold off now, hard to see this go any lower now.
Also sure PI's taking a punt with T-20's got caught out and exacerbated the recent drop.
Not writing this off but an indication from the BOD that there is a real plan would give the SP significant boost. There are options for MTFB beyond another share offering that, imo, would be a disaster at these prices eg. partnerships or further debt.
About time we turned a corner...
Can realistically see a large pharma co picking this up as anything under 10p would be still be small change (just to add to the R&D pipeline) - its worth a punt at these prices.
Silence from GL et al is not helping anyone!!
Let's hope AMP has finished selling for now. Need some recovery in the SP, way way over sold at the moment